Intraprostatic botulinum neurotoxin type a injection for benign prostatic hyperplasia: Preliminary results with a newly purified neurotoxin

Teruhiko Yokoyama, Yumiko Yamamoto, Tomonori Suzuki, Keiji Oguma, Atsushi Nagaia

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Several studies have demonstrated the efficacy of intraprostatic injection of botulinum neurotoxin type A (BoNT/A) against symptomatic benign prostatic hyperplasia (BPH). The most commonly used BoNT/A product, Botox®, forms large complexes and composed of neurotoxin (NTX) as well as non-toxic components. We purified NTX lacking non-toxic components. We investigated the efficacy of this newly purified NTX for men with BPH. Ten male patients (mean age, 70.0 years) with BPH received 100 units (prostate volume [PV] <30ml) or 200 units (PV > 30ml) of NTX injected into the prostate via a minimally invasive outpatient technique. Evaluation included uroflowmetry, postvoid residual urine volume (PVR), PV, and International Prostate Symptom Score (IPSS) measured at baseline and 1, 3, 6, and 12 months post-treatment. The status of 7 of the 10 patients examined was found to have improved within 1 month of treatment. The mean IPSS decreased from 23.8 ± 7.0 to 16.3 ± 10.3 (p - 0.0093) at 1 month, to 14.9 ± 8.2 (p = 0.0074) at 3 months, and to 16.9 ± 7.3 (p = 0.018) at 12 months. The mean PV decreased from 47.8 ± 21.2 to 39.2 ± 19.5 ml (p = 0.0076) at 3 months. The PVR improved at 3 and 6 months post-treatment Intraprostatic NTX injection induces prostate shrinkage and is effective in men with BPH.

Original languageEnglish
Pages (from-to)291-297
Number of pages7
JournalActa Medica Okayama
Volume66
Issue number4
Publication statusPublished - 2012

Fingerprint

Neurotoxins
Prostatic Hyperplasia
Prostate
Injections
Type A Botulinum Toxins
Residual Volume
Outpatients
Therapeutics
Urine

Keywords

  • Benign prostatic hyperplasia
  • Botulinum neurotoxin type A
  • Therapy

ASJC Scopus subject areas

  • Medicine(all)
  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Intraprostatic botulinum neurotoxin type a injection for benign prostatic hyperplasia : Preliminary results with a newly purified neurotoxin. / Yokoyama, Teruhiko; Yamamoto, Yumiko; Suzuki, Tomonori; Oguma, Keiji; Nagaia, Atsushi.

In: Acta Medica Okayama, Vol. 66, No. 4, 2012, p. 291-297.

Research output: Contribution to journalArticle

@article{114ac0bbf99d45d0ba0d8e7d3ced0ed2,
title = "Intraprostatic botulinum neurotoxin type a injection for benign prostatic hyperplasia: Preliminary results with a newly purified neurotoxin",
abstract = "Several studies have demonstrated the efficacy of intraprostatic injection of botulinum neurotoxin type A (BoNT/A) against symptomatic benign prostatic hyperplasia (BPH). The most commonly used BoNT/A product, Botox{\circledR}, forms large complexes and composed of neurotoxin (NTX) as well as non-toxic components. We purified NTX lacking non-toxic components. We investigated the efficacy of this newly purified NTX for men with BPH. Ten male patients (mean age, 70.0 years) with BPH received 100 units (prostate volume [PV] <30ml) or 200 units (PV > 30ml) of NTX injected into the prostate via a minimally invasive outpatient technique. Evaluation included uroflowmetry, postvoid residual urine volume (PVR), PV, and International Prostate Symptom Score (IPSS) measured at baseline and 1, 3, 6, and 12 months post-treatment. The status of 7 of the 10 patients examined was found to have improved within 1 month of treatment. The mean IPSS decreased from 23.8 ± 7.0 to 16.3 ± 10.3 (p - 0.0093) at 1 month, to 14.9 ± 8.2 (p = 0.0074) at 3 months, and to 16.9 ± 7.3 (p = 0.018) at 12 months. The mean PV decreased from 47.8 ± 21.2 to 39.2 ± 19.5 ml (p = 0.0076) at 3 months. The PVR improved at 3 and 6 months post-treatment Intraprostatic NTX injection induces prostate shrinkage and is effective in men with BPH.",
keywords = "Benign prostatic hyperplasia, Botulinum neurotoxin type A, Therapy",
author = "Teruhiko Yokoyama and Yumiko Yamamoto and Tomonori Suzuki and Keiji Oguma and Atsushi Nagaia",
year = "2012",
language = "English",
volume = "66",
pages = "291--297",
journal = "Acta Medica Okayama",
issn = "0386-300X",
publisher = "Okayama University",
number = "4",

}

TY - JOUR

T1 - Intraprostatic botulinum neurotoxin type a injection for benign prostatic hyperplasia

T2 - Preliminary results with a newly purified neurotoxin

AU - Yokoyama, Teruhiko

AU - Yamamoto, Yumiko

AU - Suzuki, Tomonori

AU - Oguma, Keiji

AU - Nagaia, Atsushi

PY - 2012

Y1 - 2012

N2 - Several studies have demonstrated the efficacy of intraprostatic injection of botulinum neurotoxin type A (BoNT/A) against symptomatic benign prostatic hyperplasia (BPH). The most commonly used BoNT/A product, Botox®, forms large complexes and composed of neurotoxin (NTX) as well as non-toxic components. We purified NTX lacking non-toxic components. We investigated the efficacy of this newly purified NTX for men with BPH. Ten male patients (mean age, 70.0 years) with BPH received 100 units (prostate volume [PV] <30ml) or 200 units (PV > 30ml) of NTX injected into the prostate via a minimally invasive outpatient technique. Evaluation included uroflowmetry, postvoid residual urine volume (PVR), PV, and International Prostate Symptom Score (IPSS) measured at baseline and 1, 3, 6, and 12 months post-treatment. The status of 7 of the 10 patients examined was found to have improved within 1 month of treatment. The mean IPSS decreased from 23.8 ± 7.0 to 16.3 ± 10.3 (p - 0.0093) at 1 month, to 14.9 ± 8.2 (p = 0.0074) at 3 months, and to 16.9 ± 7.3 (p = 0.018) at 12 months. The mean PV decreased from 47.8 ± 21.2 to 39.2 ± 19.5 ml (p = 0.0076) at 3 months. The PVR improved at 3 and 6 months post-treatment Intraprostatic NTX injection induces prostate shrinkage and is effective in men with BPH.

AB - Several studies have demonstrated the efficacy of intraprostatic injection of botulinum neurotoxin type A (BoNT/A) against symptomatic benign prostatic hyperplasia (BPH). The most commonly used BoNT/A product, Botox®, forms large complexes and composed of neurotoxin (NTX) as well as non-toxic components. We purified NTX lacking non-toxic components. We investigated the efficacy of this newly purified NTX for men with BPH. Ten male patients (mean age, 70.0 years) with BPH received 100 units (prostate volume [PV] <30ml) or 200 units (PV > 30ml) of NTX injected into the prostate via a minimally invasive outpatient technique. Evaluation included uroflowmetry, postvoid residual urine volume (PVR), PV, and International Prostate Symptom Score (IPSS) measured at baseline and 1, 3, 6, and 12 months post-treatment. The status of 7 of the 10 patients examined was found to have improved within 1 month of treatment. The mean IPSS decreased from 23.8 ± 7.0 to 16.3 ± 10.3 (p - 0.0093) at 1 month, to 14.9 ± 8.2 (p = 0.0074) at 3 months, and to 16.9 ± 7.3 (p = 0.018) at 12 months. The mean PV decreased from 47.8 ± 21.2 to 39.2 ± 19.5 ml (p = 0.0076) at 3 months. The PVR improved at 3 and 6 months post-treatment Intraprostatic NTX injection induces prostate shrinkage and is effective in men with BPH.

KW - Benign prostatic hyperplasia

KW - Botulinum neurotoxin type A

KW - Therapy

UR - http://www.scopus.com/inward/record.url?scp=84867685917&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84867685917&partnerID=8YFLogxK

M3 - Article

C2 - 22918201

AN - SCOPUS:84867685917

VL - 66

SP - 291

EP - 297

JO - Acta Medica Okayama

JF - Acta Medica Okayama

SN - 0386-300X

IS - 4

ER -